Session 26
Viral vectors

Programme

• 10:30 a.m. – 10:55 a.m. 20 Min. 5 Min.

  • Invited Talk
  • IT 35

  The development of therapeutic AAV vectors

  • Kari Airenne (Kuopio / FI)
• 10:55 a.m. – 11:10 a.m. 10 Min. 5 Min.

  • Abstract Talk
  • AT 73

  Novel alternating Arenavirus-based vector technology encoding HBV antigens generates robust antigen-specific CD8 T cell responses and high titers of anti-HBsAg antibodies

  • Sarah Ahmadi-Erber (New York, NY / US)

   Vaccines, Viral vectors
• 11:10 a.m. – 11:25 a.m. 10 Min. 5 Min.

  • Abstract Talk
  • AT 74

  Development of a Tembusu virus replicon platform for the immunization of poultry

  • Jerome Comes (Wageningen / NL)

   Vaccines, Viral vectors
• 11:25 a.m. – 11:40 a.m. 10 Min. 5 Min.

  • Abstract Talk
  • AT 75

  Recombinant Newcastle disease viruses as vector vaccines against rabies and peste-des-petits-ruminants

  • Dr. Magdalena Murr (Greifswald – Insel Riems / DE)

   Vaccines, Veterinary virology
• 11:40 a.m. – 11:55 a.m. 10 Min. 5 Min.

  • Abstract Talk
  • AT 76

  AAV2 can replicate its DNA by a rolling hairpin or rolling circle mechanism, depending on the helper virus

  • Anouk Lkharrazi (Zurich / CH)

   Viral vectors